The cytotoxicity of a conjugate composed of human epidermal growth factor and eosinophil cationic protein

Hiromitsu Jinno, Masakazu Ueda, Soji Ozawa, Tadashi Ikeda, Masaki Kitajima, Takashi Maeda, Niasaharu Seno

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Conventional targeted therapy with foreign proteins is highly immunogenic. In this study, we developed targeted therapy composed of human endogenous proteins and evaluated its efficacy in vitro. Materials and Methods: Human epidermal growth factor (EGF) was chemically linked to human eosinophil cationic protein (ECP). The cytotoxicity of the EGF-ECP conjugate was evaluated by MTT assay. Results: The conjugate showed dose-dependent cytotoxicity on EGF receptor (EGFR) -overexpressing BT-20 cells with an IC50 of 1.5 × 10-7 M, whereas the IC50 of ECP alone was almost 10 M. The conjugate had no detectable cytotoxicity against EGF receptor-deficient H69 cells. Excess EGF protected BT-20 cells from the cytotoxicity of the conjugate. Comparing the cytotoxicity and the level of EGFR expression, the cytotoxicity of the conjugate was positively correlated with the level of EGFR expression of each cell line. Conclusion: Conjugates composed solely of human proteins might be useful with less immunogenicity and less toxicity than the conventional immunotoxins for targeted therapy.

Original languageEnglish
Pages (from-to)4141-4145
Number of pages5
JournalAnticancer research
Volume22
Issue number6 C
Publication statusPublished - 2002 Nov 1

Keywords

  • Breast cancer
  • Conjugate
  • Eosinophil cationic protein
  • Epidermal growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The cytotoxicity of a conjugate composed of human epidermal growth factor and eosinophil cationic protein'. Together they form a unique fingerprint.

  • Cite this

    Jinno, H., Ueda, M., Ozawa, S., Ikeda, T., Kitajima, M., Maeda, T., & Seno, N. (2002). The cytotoxicity of a conjugate composed of human epidermal growth factor and eosinophil cationic protein. Anticancer research, 22(6 C), 4141-4145.